Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P.

Cancer Res. 2003 Dec 1;63(23):8153-7.

2.

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR; CHEK2-Breast Cancer Consortium..

Nat Genet. 2002 May;31(1):55-9.

PMID:
11967536
3.

CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.

Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ, Hogervorst FB, van den Ouweland AM, Gille JJ, Schmidt MK, van der Vaart AW, Meijers-Heijboer H, Waisfisz Q.

J Med Genet. 2011 Dec;48(12):860-3. doi: 10.1136/jmedgenet-2011-100380.

PMID:
22058428
4.

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.

Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG.

J Clin Oncol. 2008 Feb 1;26(4):542-8. doi: 10.1200/JCO.2007.12.5922. Review.

PMID:
18172190
5.

The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.

Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG.

Breast Cancer Res Treat. 2008 Dec;112(3):569-73. doi: 10.1007/s10549-007-9878-z.

PMID:
18175216
6.

A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Vahteristo P, Bartkova J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkilä P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H.

Am J Hum Genet. 2002 Aug;71(2):432-8.

7.

German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.

Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, Pierl CB, Brüning T, Ko Y, Benner A, Wichmann HE, Brauch H, Hamann U; GENICA Network..

Eur J Cancer. 2005 Dec;41(18):2896-903.

PMID:
16239104
8.

Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N; Breast Cancer Linkage Consortium..

Am J Hum Genet. 2003 Apr;72(4):1023-8.

9.

Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals.

Jekimovs CR, Chen X, Arnold J, Gatei M, Richard DJ, Spurdle AB, Khanna KK, Chenevix-Trench G; kConFab Investigators..

Br J Cancer. 2005 Feb 28;92(4):784-90.

10.

[CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China].

Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Aug;23(4):443-5. Chinese.

PMID:
16883537
11.

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.

de Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG.

J Med Genet. 2004 Oct;41(10):731-5.

12.

Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.

Adank MA, Verhoef S, Oldenburg RA, Schmidt MK, Hooning MJ, Martens JW, Broeks A, Rookus M, Waisfisz Q, Witte BI, Jonker MA, Meijers-Heijboer H.

Eur J Cancer. 2013 May;49(8):1993-9. doi: 10.1016/j.ejca.2013.01.009.

PMID:
23415889
13.

Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.

Iniesta MD, Gorin MA, Chien LC, Thomas SM, Milliron KJ, Douglas JA, Merajver SD.

Cancer Genet Cytogenet. 2010 Oct 15;202(2):136-40. doi: 10.1016/j.cancergencyto.2010.07.124.

PMID:
20875877
14.

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.

Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, Palli D, Ottini L.

Breast Cancer Res Treat. 2008 Jul;110(1):161-7.

PMID:
17661168
15.

Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.

Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E.

Isr Med Assoc J. 2007 Nov;9(11):791-6.

16.

CHEK2 1100delC and male breast cancer in the Netherlands.

Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M.

Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7.

PMID:
18759107
17.

CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.

Wasielewski M, Vasen H, Wijnen J, Hooning M, Dooijes D, Tops C, Klijn JG, Meijers-Heijboer H, Schutte M.

Clin Cancer Res. 2008 Aug 1;14(15):4989-94. doi: 10.1158/1078-0432.CCR-08-0389.

18.

Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.

de Bock GH, Mourits MJ, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG.

Int J Gynecol Cancer. 2006;16 Suppl 2:552-5.

PMID:
17010071
19.

CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours.

Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams RD, Bevan S, Bishop K, McGuire S, Houlston RS, Eeles RA.

Br J Cancer. 2002 Dec 2;87(12):1445-8.

20.

Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.

Manoukian S, Peissel B, Frigerio S, Lecis D, Bartkova J, Roversi G, Radice P, Bartek J, Delia D.

Breast Cancer Res Treat. 2011 Nov;130(1):207-15. doi: 10.1007/s10549-011-1548-5.

PMID:
21562711

Supplemental Content

Support Center